Q1 Earnings Estimate for KZR Issued By William Blair

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Kezar Life Sciences in a research note issued to investors on Tuesday, March 25th. William Blair analyst M. Phipps expects that the company will post earnings of ($2.95) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($4.39) per share. William Blair also issued estimates for Kezar Life Sciences’ Q2 2026 earnings at ($3.03) EPS, Q3 2026 earnings at ($3.10) EPS and Q4 2026 earnings at ($3.16) EPS.

Several other research analysts have also recently weighed in on KZR. Wells Fargo & Company cut their price objective on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 19th. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Price Performance

Kezar Life Sciences stock opened at $5.13 on Friday. The stock has a market cap of $37.43 million, a P/E ratio of -0.39 and a beta of 0.49. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average price is $6.02 and its two-hundred day moving average price is $6.69. Kezar Life Sciences has a 52 week low of $5.01 and a 52 week high of $9.38.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.71) by ($0.06).

Institutional Investors Weigh In On Kezar Life Sciences

A number of hedge funds have recently modified their holdings of the stock. Ikarian Capital LLC increased its position in Kezar Life Sciences by 23.0% in the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares during the last quarter. Peapod Lane Capital LLC bought a new position in shares of Kezar Life Sciences during the 4th quarter worth $833,000. Geode Capital Management LLC increased its holdings in Kezar Life Sciences by 15.0% in the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after acquiring an additional 81,678 shares during the last quarter. Shay Capital LLC bought a new stake in Kezar Life Sciences in the 4th quarter valued at about $398,000. Finally, BML Capital Management LLC purchased a new stake in Kezar Life Sciences during the fourth quarter valued at about $327,000. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.